Tandem Diabetes Care (Nasdaq:TNDM) announced today that it signed a multi-year R&D collaboration agreement with the University of Virginia (UVA).
The collaboration with the UVA Center for Diabetes Technology aims to advance R&D efforts on fully automated, closed-loop insulin delivery systems. Tandem develops its own closed-loop systems, including the t:slim X2 and Mobi pumps, which utilize Control IQ technology.
San Diego-based Tandem plans to rely on UVA’s work to improve care for patients with diabetes through technology-based interventions. The company also noted UVA’s success in translating automated insulin delivery algorithms into medical devices around the world. Tandem said it brings its own market-leading expertise in insulin delivery, algorithm implementation and data management.
The collaboration expands on Tandem’s ongoing research into advancing automated closed-loop insulin delivery. Tandem and UVA plan to involve scientists, clinicians and functional experts from both institutions. They believe results could lead to clinical research to accelerate approved uses for Tandem’s next-generation insulin delivery systems.
“Our past work with UVA, including research related to our automated insulin delivery systems as part of the International Diabetes Closed Loop trials, helped contribute to life-changing products for the diabetes community,” said John Sheridan, Tandem president and CEO. “We believe this research collaboration will continue on our joint history of delivering new innovations that can further improve the lives of people living with diabetes.”
Tandem agreed to provide funding, technology and supplies in the collaboration.
“After more than 10 years working with the Tandem team, this is an exciting new beginning for our collaboration to serve patients with diabetes,” said Marc Breton, UVA Center for Diabetes Technology associate director for research. “Together, we will expand our research efforts into automated insulin delivery with the goal of once more substantially enhancing care and quality of life for patients around the world.”
